Anyway, since the 12 patients with heterozygous 22q deletion and/or a copy number gain of SMARCB1 showed reduced expression of SMARCB1/INI1 at immunohistochemistry, it is possible that this partial loss of SMARCB1/INI1 is a marker of the accumulation of additional mutations as suggested by Bai et al., who reported complex copy number alterations, including also the deletion of 22q, without apparent recurrent oncogene mutations in conventional chordoma (29). The gene discussed is SMARCB1; the disease is chordoma.